ACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
ACNS2021
What is the goal of the study?
ACNS2021 is built on the backbone of the Induction chemotherapy used in ACNS0122 and ACNS1123, the excellent outcomes of ACNS0122, and the pattern of relapse seen in ACNS1123 (predominantly spine). As compared to ACNS1123, this study will add back spinal radiation in an attempt to reduce relapses in the spine. While the addition of spinal radiation may increase morbidity, modern radiation techniques are capable of minimizing radiation exposure to tissues anterior to the spinal canal. The greatest morbidity from CSI for most patients is whole brain radiation therapy (WBRT). This study will use WVI (as used in ACNS1123) rather than WBRT (as used in ACNS0122) with the intent of minimizing neurocognitive and other late effects of WBRT. Whole ventricle spinal canal irradiation (WVSCI) is a novel radiation volume. The reduced dose of 30.6 Gy for microscopic disease used in ACNS1123 will also be used in ACNS2021, as no relapses were seen in the ventricles on ACNS1123.
Who can participate in the study?
Please contact the study team listed below to learn more.